SCHEMBL119026

SCHEMBL119026

COC(=O)c1ccc(S(=O)(=O)NCC2CCCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.71
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 3/20 0.54
USP2 O75604 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
STAT3 P40763 1/20 0.54
HTT P42858 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CYP2C9 P11712 1/20 0.53
GBA1 P04062 1/20 0.51
PKM P14618 1/20 0.51
POLB P06746 2/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120151 0.99 KMT2A (0.73) KMT2AALDH1A1SMN1; SMN2MEN1USP2
SCHEMBL119739 0.97 KMT2A (0.67) KMT2AALDH1A1SMN1; SMN2MEN1USP2
SCHEMBL21309892 0.82 KMT2A (0.60) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL8030757 0.81 ALDH1A1 (0.65) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL28644166 0.80 HDAC3 (0.76) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL29183291 0.80 ALDH1A1 (0.64) KMT2AALDH1A1SMN1; SMN2MEN1USP2
SCHEMBL7699722 0.78 KMT2A (0.68) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL118528 0.78 KDM4E (0.60) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL25440166 0.77 MGLL (0.77) KMT2AALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL3853011 0.76 KMT2A (0.74) KMT2AALDH1A1SMN1; SMN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KMT2A 941/4885ALDH1A1 1996/4885SMN1; SMN2 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.